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Purpose: To evaluate the performance of artificial neural networks (aNN) applied to
preoperative 18F-FDG PET/CT for predicting nodal involvement in non-small-cell lung
cancer (NSCLC) patients.
Methods: We retrospectively analyzed data from 540 clinically resectable NSCLC
patients (333 M; 67.4 ± 9 years) undergone preoperative 18F-FDG PET/CT and
pulmonary resection with hilo-mediastinal lymphadenectomy. A 3-layers NN model
was applied (dataset randomly splitted into 2/3 training and 1/3 testing). Using
histopathological reference standard, NN performance for nodal involvement (N0/N+
patient) was calculated by ROC analysis in terms of: area under the curve (AUC), accuracy
(ACC), sensitivity (SE), specificity (SP), positive and negative predictive values (PPV, NPV).
Diagnostic performance of PET visual analysis (N+ patient: at least one node with uptake
≥ mediastinal blood-pool) and of logistic regression (LR) was evaluated.
Results: Histology proved 108/540 (20%) nodal-metastatic patients. Among all
collected data, relevant features selected as input parameters were: patients’ age, tumor
parameters (size, PET visual and semiquantitative features, histotype, grading), PET
visual nodal result (patient-based, as N0/N+ and N0/N1/N2). Training and testing NN
performance (AUC = 0.849, 0.769): ACC = 80 and 77%; SE = 72 and 58%; SP
= 81 and 81%; PPV = 50 and 44%; NPV = 92 and 89%, respectively. Visual PET
performance: ACC = 82%, SE = 32%, SP = 94%; PPV = 57%, NPV = 85%. Training
and testing LR performance (AUC = 0.795, 0.763): ACC = 75 and 77%; SE = 68
and 55%; SP = 77 and 82%; PPV = 43 and 43%; NPV = 90 and 88%, respectively.
Taralli et al. NSCLC Nodal-Staging: 18FDG-PET/CT and aNN
Conclusions: aNN application to preoperative 18F-FDG PET/CT provides overall good
performance for predicting nodal involvement in NSCLC patients candidate to surgery,
especially for ruling out nodal metastases, being NPV the best diagnostic result; a high
NPV was also reached by PET qualitative assessment. Moreover, in such population
with low a priori nodal involvement probability, aNN better identify the relatively few and
unexpected nodal-metastatic patients than PET analysis, so supporting the additional
aNN use in case of PET-negative images.
Keywords: PET/CT, 18F-FDG, non-small-cell lung cancer, artificial neural network, nodal staging
INTRODUCTION
The evaluation of lymph nodal status is of paramount
importance for selecting the optimal therapeutic approach
in patients with non-small-cell lung cancer (NSCLC), with
N0 and N1 patients addressed to surgery (when clinically
feasible), and N3 ones to non-surgical approaches, while N2
patients still have more controversial therapeutic options
(1, 2). 18-Fluorine-Fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography (18F-FDG PET/CT)
is widely used for nodal staging in NSCLC patients, being
recommended by the National Comprehensive Cancer
Network (NCCN) guidelines (1). 18F-FDG PET/CT shows
an overall good accuracy for nodal evaluation with sensitivity
and specificity values ranging from 72 to 90% and from
81 to 95%, respectively (1–6). More recently, machine
learning methods have been applied to 18F-FDG PET/CT
as an advanced and innovative analysis tool in NSCLC
patients for staging, treatment evaluation and prognostic
stratification (7–10).
Neural Networks (NN) represent an application of
machine learning based on an artificial reinterpretation
of the human brain structure, that relies on the use of
numerous layers of “neurons.” Each neuron is characterized
by a specific weight and importance in the context of
the whole network. Similarly, each layer receives data,
calculates scores and passes the output of the analysis to
the next layer in a self-learning process. This architecture
has been recently widely used in the context of biomedical
imaging research and radiation oncology, aiming to predict
clinical outcomes and enrich diagnostic information,
describing the interactions and complex simultaneous
relationships of variables belonging to different domains
(11–13). Growing, although still limited, literature evidence
has explored the application of NN to 18F-FDG PET/CT
for predicting nodal involvement in NSCLC patients,
but burdened by differences in clinical and procedural
aspects (14–17).
Aim of our study was to evaluate the performance
of artificial neural network (aNN) applied to
preoperative 18F-FDG PET/CT for predicting




We retrospectively reviewed medical records of all consecutive
patients referred to the PET/CT center of “Fondazione
Policlinico Universitario Agostino Gemelli IRCCS” in Rome
by a local Thoracic Surgery Unit between January 2007
and December 2017 for pulmonary lesions’ evaluation. We
included only patients with: (1) malignant pulmonary lesions
histologically proven as NSCLC; (2) judged resectable at pre-
operative Multidisciplinary Tumor Board evaluation (including
those with single N2 station at pre-operative invasive mediastinal
staging); (3) undergone lung resection and hilo-mediastinal
lymphadenectomy; (4) not addressed to induction chemotherapy
and/or radiotherapy. Exclusion criteria were: all patients not
fitting the inclusion criteria; with proven N2 multistation
or N3 at invasive mediastinal staging procedures. A set of
clinical, anatomic, metabolic and histopathological data were
retrospectively collected. Pathological TNM staging was defined
according to the 8th staging system edition (18, 19). This
retrospective study was approved by the local institution’s ethics
committee (Comitato Etico Lazio 1). For each patient, PET/CT
imaging was performed in the clinical routine with written
informed consent.
18F-FDG PET/CT Image Acquisition and
Interpretation
All PET/CT were acquired according to standard protocol
(6 h fasting-state, blood glucose levels <150 mg/dl; acquisition
time of 60 ± 10min post-injection of 185–370 MBq of 18F-
FDG, according to BMI), using an integrated 3D PET/CT
device (Gemini GXL by Philips Medical System, Cleveland,
Ohio or Biograph mCT by Siemens Healthineers, Chicago,
Illinois) with a low-dose unenhanced CT scan (120 kV, 50–
80mA) for anatomical localization and attenuation correction.
All PET images (reconstructed with iterative algorithms) were
evaluated by two independent nuclear medicine physicians (ST,
VS), blinded to the final pathological TNM staging, using a
dedicated fusion and display software (Syngo.via MM Oncology
software; Siemens Medical Solutions). For primary lung tumor
evaluation, a qualitative analysis was performed: PET was scored
as positive if 18F-FDG uptake was equal or higher than the
mediastinal blood-pool, as negative if lower. A semiquantitative
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TABLE 1 | Main clinical, anatomic, metabolic, and histopathological






Mean ± SD 67.4 ± 9
Tumor size (mm)
Mean ± SD 25.3 ± 14.3
Tumor location
Right lung 293 (54.2%)
Upper lobesa 348 (64.4%)
Centralb 146 (27%)




Mean ± SD 6.6 ± 5.6
Tumor SUVmean
Mean ± SD 4.2 ± 3.4
MTV (cm3)
Mean ± SD 7.6 ± 16.7
TLG
Mean ± SD 52.6 ± 182.1
Nodal visual PET result
Nodal status 479 N0 (88.7%), 61 N+ (11.3%)
Nodal staging 479 N0 (88.7%), 27 N1 (5%), 34 N2 (6.3%)
Histology
Adenocarcinoma 385 (71.3%)




G1–G2, G2 26 (4.8%), 201 (37.2%)
G2–G3, G3 68 (12.6%), 167 (31%)
G4 5 (0.9%)




SD, standard deviation; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
aThe right middle lobe and lingula were included in the upper lobes location.
bThe lung lesion was defined as central if located in the inner one-third of the lung
parenchyma, and as peripheral if located in the outer two-thirds of lung parenchyma.
analysis was also performed: for lesions segmentation, a fixed
relative threshold method was adopted and a 3D volumetric
region of interest (VOI) was drawn semi-automatically over the
primary tumor on fused PET/CT images, with a fixed threshold
of 40% of the maximum standardized uptake value. Then, the
following tumor semiquantitative parameters were extracted,
applying the EQ·PET quantification technology (20): maximum
and mean standardized uptake values (SUVmax, SUVmean),




Location T (right/left lung) 0.22
Location T (upper/lower lobe) 0.57
Site T (central/peripheral) 1.00
Histology T0 (neuroendocrine tumor)b 0.95
Histology T1 (adenocarcinoma)b 0.94
Histology T2 (squamous cell carcinoma)b 0.97
Histology T3 (adeno-squamous carcinoma)b 1.00
Histology T4 (pleomorphic carcinoma)b 0.84
Histology T5 (poorly differentiated carcinoma)b 0.35
Grading T0 (G1–G2)b 0.65
Grading T1 (G1)b 0.27
Grading T2 (G2)b 0.61
Grading T3 (G3)b 0.25
Size T (mm)a 0.52





PET result N (negative/positive) 0.51
PET staging N0 (N0/not N0)b 0.51
PET staging N1 (N1/not N1)b 1.00
T, tumor; N, nodal.
aNumerical features were Z-standardized.
bCategorical features were binarized.
metabolic tumor volume (MTV, expressed in cm3) and total
lesion glycolysis (TLG, defined as the product of SUVmean and
MTV). The anatomical consistency of tumor delineation was
visually checked and volumetric region of interest was adjusted
manually, if needed. For nodal evaluation, a visual patient-based
PET nodal status was defined: any lymph node with 18F-FDG
uptake ≥ mediastinal blood-pool was classified as PET positive;
each patient with at least one positive lymph node was scored
as PET positive (PET N+), otherwise as negative (PET N0).
Moreover, for each patient a PET nodal staging (PET N0, N1, N2,
or N3) was defined, according to sites of PET positive nodes and
the 8th edition of TNM staging. Any disagreement was resolved
by consensus. Histological nodal status was used as reference
standard to verify PET results.
Neural Network Development
The collected clinical, anatomic, metabolic, and histopathological
features were used as input parameters of the model: patients’
age and gender, tumor size and location (as right/left lung,
upper/lower lobes, and central/peripheral), PET tumor visual
result and semiquantitative parameters, PET nodal status, PET
nodal staging, tumor histotype and grading. Categorical features
were binarized and numerical features were Z-standardized. The
dataset was randomly split into 2/3 training and 1/3 testing, being
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FIGURE 1 | Relevant features (highlighted in green) to the outcome of interest (pathological nodal involvement) selected with Boruta algorithm.
the sample size numerous enough to perform hold-out validation
instead of cross-validation. Relevant features to outcome of
interest (i.e., surgically-proven nodal status) were selected with
Boruta algorithm on the training set (21). A NN based model
was then realized with the selected features. Considering the
sample size, the events distribution and the number of selected
features, a 3-layers neural network (12, 6, and 2 activation
neurons, respectively) was trained on the training set with the
Boruta-selected features as input. Network training specifications
were as follows: the first two layers had activation function
ReLu, while the third layer (classification layer) had Softmax.
Categorical cross-entropy was the loss function and Adam was
the optimizer. The model was trained for 500 epochs with 150
batch size and 0.1 validation split. Classification performance
of the trained network in predicting nodal involvement was
evaluated on the testing set applying the Receiver Operating
Characteristic (ROC) analysis, using histological nodal status
as reference standard. Logistic regression (LR) model was also
trained on the training set after Akaike information criterion
(AIC)-based stepwise selection on the Boruta-selected features.
Statistical Analysis
Continuous variables were expressed as mean (with standard
deviation) or median (with range) and categorical data as a
percentage. Comparison between training and testing groups in
collected features were performed using Mann–Whitney/Chi-
square test for continuous and categorical data, respectively.
On ROC analysis, the NN diagnostic performance for nodal
involvement (on both training and testing sets) was calculated in
terms of Area Under the Curve (AUC) and classification matrix
at the Youden-index classification threshold were computed:
accuracy (ACC), sensitivity (SE), specificity (SP), positive
and negative predictive values (PPV and NPV). Diagnostic
performances for nodal involvement (N0/N+) of the visual PET
analysis and LR model (on both training and testing sets) were
also assessed. PPV and NPV were calculated assuming that
the individual pre-test probability of nodal metastatic disease
was equal to the prevalence of pathological nodal involvement
(pN+) found in our population. Results were reported with 95%
Confidence Intervals (CIs). Statistical significance was set at p




Finally, 540 consecutive clinically resectable NSCLC patients (333
males; mean age: 67.4 ± 9 years), who underwent pre-operative
18F-FDG PET/CT (44 ± 28 days before surgery) were selected.
Table 1 reports the main characteristics of the study population.
Among the 540 patients, 528 underwent lobectomy, nine bi-
lobectomy and three atypical pulmonary resection. A total of
1,620 nodal stations (from station 2 to 11) were histologically
evaluated (3 ± 1 stations per patient), with a total of 4,158
examined nodes (8 ± 5 nodes per patient); peribronchial nodes
found in the resected lobe were also pathologically assessed in
439 patients. Histopathological nodal involvement was found in
108/540 (20%) patients: 45/108 staged as pN1 and 63/108 as pN2.
Overall, in the total 540 patients, 80% resulted as pN0, 8.3% as
pN1 and 11.7% as pN2. According to pathologic staging, 383
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TABLE 3 | Diagnostic performance of neural network, logistic regression, and visual 18F-FDG PET/CT analysis for pathological nodal involvement.
Training set (n = 356) Test set (n = 184) All dataset (n = 540)
NN LR NN LR PET visual analysis
AUC (95%CI) 0.849 (0.751–0.838) 0.795 (0.700–0.800) 0.769 (0.699–0.827) 0.763 (0.669–0.820) n.a.
ACC (95%CI) 0.80 (0.75–0.84) 0.75 (0.70–0.80) 0.77 (0.70–0.83) 0.77 (0.70–0.83) 0.82 (0.78–0.85)
SE (95%CI) 0.72 (0.60–0.82) 0.68 (0.56–0.73) 0.58 (0.41–0.74) 0.55 (0.38–0.72) 0.32 (0.24–0.42)
SP (95%CI) 0.81 (0.76–0.86) 0.77 (0.72–0.82) 0.81 (0.74–0.87) 0.82 (0.75–0.88) 0.94 (0.91–0.96)
PPV (95%CI) 0.50 (0.40–0.60) 0.43 (0.34–0.53) 0.44 (0.30–0.59) 0.43 (0.29–0.59) 0.57 (0.45–0.69)
NPV (95%CI) 0.92 (0.88–0.95) 0.90 (0.86–0.94) 0.89 (0.82–0.93) 0.88 (0.81–0.93) 0.85 (0.81–0.88)
NN, neural network; LR, logistic regression; AUC, area under the curve; CI, confidence interval; ACC, accuracy; SE, sensitivity; SP, specificity; PPV, positive predictive value; NPV,
negative predictive value.
FIGURE 2 | Receiver Operating Characteristic (ROC) curve for prediction of nodal involvement according to NN analysis in the training set (A) and in the testing set (B).
patients were classified as stage I (28 IA1; 152 IA2; 78 IA3; 125
IB), 74 stage II (13 IIA; 61 IIB), 80 stage III (70 IIIA; 10 IIIB), and
3 stage IVA (for pleural localizations).
Neural Network Analysis
No features differences (p > 0.05) were observed between
training and testing sets (Table 2), that also showed the
same proportion of pN0 and pN+ patients. From the set of
collected features, Boruta algorithm selected 13 relevant as
input parameters (Figure 1): patients’ age, tumor size, PET
tumor parameters (visual result, SUVmax, SUVmean, TLG,
MTV), patient-based PET nodal status (as N0/N+) and PET
nodal staging (as N0/N1/N2), tumor histotype (adenocarcinoma,
squamous cell carcinoma) and grading (G3). The NN was then
trained with all Boruta-selected features as input variables. From
ROC analysis, NN diagnostic performance for nodal involvement
(N+/N0) for the training and testing sets were: AUC = 0.849
(95%CI: 0.751–0.838), ACC= 0.80 (95%CI: 0.75–0.84), SE= 0.72
(95%CI: 0.60–0.82), SP = 0.81 (95%CI: 0.76–0.86), PPV = 0.50
(95%CI: 0.40–0.60), NPV = 0.92 (95%CI: 0.88–0.95), and AUC
= 0.769 (95%CI: 0.699–0.827), ACC = 0.77 (95%CI: 0.70–0.83),
SE = 0.58 (95%CI: 0.41–0.74), SP = 0.81 (95%CI: 0.74–0.87);
PPV= 0.44 (95%CI: 0.30–0.59), NPV= 0.89 (95%CI: 0.82–0.93),
respectively (Table 3 and Figure 2).
18F-FDG PET/CT
On PET visual analysis, 479/540 patients were classified as N0:
406/479 with no pathological nodal involvement (pN0, PET true-
negatives), 73/479 with at least one metastatic node (pN+, PET
false-negatives). The remaining 61/540 patients were classified
as PET positive for nodal involvement: 35/61 histologically
confirmed (pN+, PET true-positives), 26/61 with no pathological
nodes (pN0, PET false-positives). Diagnostic performance of PET
visual analysis for nodal involvement (N0/N+) was: ACC =
Frontiers in Medicine | www.frontiersin.org 5 April 2021 | Volume 8 | Article 664529
Taralli et al. NSCLC Nodal-Staging: 18FDG-PET/CT and aNN
FIGURE 3 | 18F-FDG PET/CT maximum intensity projection (A), transaxial fused (B), and coregistered CT images (C) of a 57-year-old female with lung
adenocarcinoma of the right lower lobe (maximum axial diameter: 30mm), showing increased metabolic activity in the primary tumor lesion (SUVmax: 12.14;
SUVmean: 7.52; MTV: 3.32 cm3; TLG: 24.98) and a focus of increased tracer uptake in a subcarinal mediastinal lymph node (D,E). According to visual analysis, the
patient was classified as PET positive for nodal involvement (PET N+). Further histopathological examination revealed no pathological nodal involvement (pN0, PET
false-positive). Artificial NN correctly classified the patient as N0.
0.82 (95%CI: 0.78–0.85), SE = 0.32 (95%CI: 0.24–0.42), SP =
0.94 (95%CI: 0.91–0.96), PPV = 0.57 (95%CI: 0.45–0.69), NPV
= 0.85 (95%CI: 0.81–0.88) (Table 3). When considering PET
nodal staging, among the 479 PET negative patients, 406/479
(84.8%) were correctly staged resulting pN0, 73/479 (15.2%)
were upstaged resulting pN1 (30/73) or pN2 (43/73). Regarding
the 61 PET positive patients, 27 were classified as PET N1
and 34 as PET N2. Among PET N1 patients, 11/27 were
correctly staged resulting pN1, 8/27 were downstaged resulting
pN0 and 8/27 were upstaged resulting pN2. Among PET N2
patients, 12/34 were correctly staged resulting pN2, 22/34 were
downstaged resulting pN1 (4/22) or pN0 (18/22). PET/CT images
of illustrative cases are reported in Figures 3, 4.
The LR model with stepwise selection based on AIC criteria
gave the model in Table 4. Logistic regression diagnostic
performance for nodal involvement at training and testing group
were: AUC = 0.795 (95%CI: 0.700–0.800), ACC = 0.75 (95%CI:
0.70–0.80), SE = 0.68 (95%CI: 0.56–0.73), SP = 0.77 (95%CI:
0.72–0.82), PPV= 0.43 (95%CI: 0.34–0.53), NPV= 0.90 (95%CI:
0.86–0.94), and AUC= 0.763 (95%CI: 0.669–0.820), ACC= 0.77
(95%CI: 0.70–0.83), SE = 0.55 (95%CI: 0.39–0.72), SP = 0.82
(95%CI: 0.75–0.88), PPV= 0.43 (95%CI: 0.29–0.59), NPV= 0.88
(95%CI: 0.81–0.93), respectively (Table 3).
DISCUSSION
Aim of our study was to evaluate the diagnostic performance
of aNN to preoperative 18F-FDG PET/CT for predicting
pathological nodal involvement in clinically resectable NSCLC
patients. The main strength points of this study are: the largest
lung cancer population on which NN were applied for the same
aim; the use of the widest combination of clinical, anatomic,
metabolic, and histopathological features as input parameters;
the surgical lymphadenectomy as golden reference in all patients.
From our results, aNN provided overall good performance
for predicting pathological nodal involvement with a diagnostic
accuracy >75% at both training and testing sets; similar
diagnostic performance on both datasets suggests that overfitting
was successfully reduced, supporting the reliability of the results.
NN showed higher specificity and NPV than sensitivity and
PPV, providing the best diagnostic performance for ruling out
nodal metastases. In this context, it has to be considered that
the pre-test probability of nodal involvement (and in turn
the positive and negative predictive values) mainly depends
on the NSCLC clinical settings. Indeed, our population has
low a priori probability of nodal involvement since deemed
clinically resectable, as confirmed by the low prevalence of
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FIGURE 4 | 18F-FDG PET/CT maximum intensity projection (A), transaxial fused (B), and coregistered CT images (C) of a 64-year-old male with lung adenocarcinoma
of the left lower lobe (maximum axial diameter: 32mm), showing increased metabolic activity in the primary tumor lesion (A) (SUVmax: 8.95; SUVmean: 5.42; MTV:
6.34 cm3; TLG: 34.37), with no abnormal focus of increased tracer uptake in hilo-mediastinal lymph nodes (D,E). According to visual analysis, the patient was
classified as PET negative for nodal involvement (PET N0). Further histopathological examination revealed metastatic homolateral hilar nodes (pN+, PET
false-negative). Artificial NN correctly classified the patient as N+.
nodal-metastatic patients and the high NPV. On the other hand,
preoperatively identifying the relatively few and unexpected
nodal-metastatic patients assumes great relevance, since other
treatment strategies rather than the planned up-front surgery can
be considered. However, PET visual analysis provided a poor
sensitivity, with occult lymph nodal metastases mainly due to
small size of metastatic lymph nodes, nodal micro-metastases
(22) or metastatic hilar nodes masked by the intense activity
of close primary tumor (14, 23). Although suboptimal, the
sensitivity provided by aNN resulted relevantly higher than visual
analysis (72 vs. 32%, respectively), suggesting that aNN may
reduce the chance of 18F-FDG PET/CT false negative results.
From a practical point of view, this finding may support the
additional use of aNN to the PET/CT reporting activity in case of
visually negative images. This diagnostic advantage of aNN may
be attributed to the intrinsic properties of this machine learning
method, able to explore and recognize complex and generally
non-linear relationships among multiple variables, obviously
going beyond the PET visual assessment alone.
Analyzing the relevant features selected by Boruta
algorithm as input parameters, the metabolic features were
the most numerous (8/13) and the first ones in order of
importance: PET nodal staging (N0/N1/N2) in the first position,
followed by PET nodal status (N0/N+) and semiquantitative





Intercept −2.071 1.480 0.1
Tumor histology (squamous cell carcinoma) −1.595 0.518 0.002
Tumor grading (G3) 1.121 0.309 0.0003
PET tumor result (positive) 2.318 1.032 0.02
PET nodal result (positive) 1.436 0.473 0.002
PET nodal staging (N1) 1.038 0.724 0.1
Patient age −0.029 0.017 0.08
parameters. We may suppose that PET nodal staging resulted
as the most relevant feature since it appears intrinsically
more linked to the target output (i.e., pathological nodal
status) than other variables, providing direct and complete
information on nodal assessment (even more detailed than
dichotomous PET nodal status). When considering the PET
semiquantitative tumor-related parameters, their relevance
seems to be expected, being widely reported in literature
as predictive factors of pathological nodal involvement in
NSCLC (24–31).
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Visual analysis of primary lesion resulted the last relevant
metabolic feature. This finding may be reasonably attributed to
its dichotomous nature (uptake ≥ or < mediastinal blood-pool
activity) compared to the continuous nature of semiquantitative
parameters (wide range of uptake levels), so providing less
detailed information on tumormetabolism. Among the anatomic
variables, tumor size resulted the only relevant feature: it was
already reported to be a predictive factor for nodal involvement
(26, 32) since reflecting the T-classificator in the TNM staging,
and the risk of lymph node involvement increases with the
increase of T stage. Lastly, among histological variables, the
relevance of G3 (grading-feature) appears in line with the
expectations: high grading, reflecting high tumor aggressiveness,
increases the risk of metastatic nodal involvement (33), as also
observed in our study, with a higher rate of nodal-metastatic
patients in G3 group than in well or moderately differentiated
groups (34.1 vs. 11.3%). Finally, regarding tumor histotype, more
nodal metastases in adenocarcinomas than in squamous cell
carcinomas were observed in our population (21.8 vs. 10.1%),
supposing that adenocarcinoma type would be more informative
for aNN regarding the risk of nodal involvement. Nevertheless,
adenocarcinoma resulted a relatively weaker input parameter
than the other one, in line with literature, as no concordant and
definitive results on the greater or lesser predictive role of one or
the other histotype have emerged (26, 27, 34, 35).
In our study, the LR results were only slightly lower compared
to NN. A neural network is more complex than LR since one
can think of it as a subset of a neural network classifier. LR
model can always be simulated using a NN with one hidden
node with the identity activation function and one output node
with zero bias and logistic sigmoid activation. This finding
can suggest that, when applying aNN to 18F-FDG PET for
predicting nodal metastases, the added value of modeling non-
linear interactions is not sufficient to substantially increase the
diagnostic performance, also given the strong association of input
variables (primarily PET-related) with the outcome.
Few studies in literature evaluated the application of aNN to
18F-FDG PET/CT in NSCLC for predicting nodal involvement,
with several differences in clinical and procedural aspects among
single studies and when compared to our work. In particular,
Vesselle et al. (14) and Toney et al. (15), investigating 133
NSCLC patients, reported a NN accuracy higher than accuracy
of PET expert reader (87.3 and 99.2% vs. 73.5 and 72.4%,
respectively). This result seems to outperform the performance
reported in our study. However, both authors reported an
increased PET accuracy and closer to NN performance (up
to 92.2%) when N status was dichotomized in N0+N1 vs.
N2+N3 disease. Moreover, it has to be considered that both
studies are not comparable to our work due to several
aspects (smaller population, inclusion of non-surgically treated
patients, heterogeneous reference standard, higher rate of nodal-
metastatic patients, fewer input parameters and without PET-
volumetric ones) and, mainly, to the criteria used for PET visual
nodal analysis, that likely affect the comparison between PET
and NN performance. Indeed, nodes have been interpreted as
benign or malignant according on the expert reader’s clinical
experience, taking into account also size, location, and activity
of primary tumor and size of the most metabolically active node.
On the contrary, we used a strictly metabolic, more standardized,
reproducible and objective criterion, interpreting nodes as
benign or malignant only based on the mediastinal blood-
pool activity. Anyway, the value of adding morphological nodal
information for PET interpretation appears negligible in our
population of clinically resectable patients, being almost all nodes
with short axis ≤ 10mm. Among other two studies focused on
the same topic (16, 17), only one compared NN with PET visual
performance, reporting similar accuracy, higher NN sensitivity
and lower NN specificity for predicting nodal involvement.
However, differences in population and/or methodological
aspects make both studies not directly comparable to our
paper. Finally, our study used the widest combination of
clinical, anatomic, metabolic and histopathological data as input
parameters, while only morpho-anatomic and/or metabolic
features were considered in all the four previous studies;
in addition, none of these studies reported LR model for
comparison with aNN performance.
We acknowledge some limitations of our study, mainly
represented by its retrospective nature. Moreover, a selection
bias has to be considered, since only NSCLC patients candidate
to surgical resection were included in our analysis, inherently
lowering the prevalence of lymph nodal involvement. This aspect
could have made our results generalizable only to similar cohorts
of NSCLC patients, also affecting the diagnostic performance,
especially in terms of PPV (due to the low rate of true positive
patients). On the other hand, selecting only patients with surgical
nodal evaluation allowed a reliable and robust verification of our
results. Finally, external data validation was not applied.
In conclusion, the application of aNN to preoperative
18F-FDG PET/CT, along with clinical, anatomic and
histopathological features, provides overall good performance
for predicting pathological nodal involvement in clinically
resectable NSCLC patients, especially for ruling out nodal
metastases. Compared to visual PET analysis, aNN seem able
to reduce the chance of PET false negative results; this finding
assumes particular relevance in a population of clinically
resectable NSCLC patients, with low a priori probability of
nodal involvement, when the identification of the relatively few
and unexpected nodal-metastatic patients may change their
planned treatment strategies and also impact on prognosis. From
a practical point of view, our observations may support the
additional use of aNN to the PET/CT reporting activity in case of
visually negative images. The application of aNN for categorizing
pathological nodal involvement in N1 vs. N2 disease is topic of
further ongoing analyses.
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